AtriCure Inc. (ATRC) PT Raised to $64 at Canaccord Genuity

Canaccord Genuity analyst William Plovanic raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $64.00 (from $53.00) while maintaining a Buy rating.

The analyst commented: 'ATRC reported Q3/25 revenue of $134.3M (+15.1% Y/Y CC), ahead of CGe of $131.6M and consensus of $131.3M. Adjusted EBITDA of $17.8M was well ahead of our $13.3M estimate and consensus of $11.7M, as ATRC continues to deliver strong gross margins and solid SG&A leverage. The beat was driven by continued growth in the company’s EnCompass and AtriClip products. The company raised its revenue guidance to reflect the beat, which we believe reflects the conservative nature of the company’s projections. ATRC also raised its adjusted EBITDA guidance but continues to signal that it will invest in R&D, such as the start of the BoxX-NoAF trial and continued follow-up on LeAAPS. With continued solid growth and improving profitability, we reiterate our BUY rating and increase our PT to $64 from $53 on comp group multiple expansion and increased expectations."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters